Table 7.
OPERA Cohort: Baseline Demographic and Clinical Characteristics of Patients Initiating Treatment with Abacavira
| Parameter | All ABC initiators N=9619 | Started ABC in pre–HLA‐B*5701 screening period (N=3215) | Started ABC in post–HLA‐B*5701 screening period (N=6404) | p value |
|---|---|---|---|---|
| Age, yrs, n (%) | ||||
| Median (IQR) | 42.8 (34.7–50.5) | 40.4 (34.9–46.4) | 44.6 (34.6–52.0) | < 0.0001 |
| 13–25 | 670 (7.0) | 127 (4.0) | 543 (8.5) | < 0.0001 |
| 26–49 | 6424 (66.8) | 2577 (80.2) | 3847 (60.1) | |
| 50+ | 2525 (26.3) | 511 (15.9) | 2014 (31.4) | |
| Sex, n (%) | ||||
| Male | 8089 (84.1) | 2759 (85.8) | 5330 (83.2) | < 0.0001 |
| Female | 1500 (15.6) | 429 (13.3) | 1071 (16.7) | |
| Unknown | 30 (0.3) | 27 (0.8) | 3 (0.05) | |
| Race, n (%) | ||||
| African American | 3240 (33.7) | 865 (26.9) | 2375 (37.1) | < 0.0001 |
| Not African American | 6379 (66.3) | 2350 (73.1) | 4029 (62.9) | |
| Ethnicity, n (%) | ||||
| Hispanic | 2161 (22.5) | 615 (19.1) | 1546 (24.1) | < 0.0001 |
| Not Hispanic | 7458 (77.5) | 2600 (80.9) | 4858 (75.9) | |
| Risk of infection, n (%) | ||||
| MSM | 5014 (52.1) | 1969 (61.2) | 3045 (47.5) | < 0.0001 |
| Not MSM | 4605 (47.9) | 1246 (38.8) | 3359 (52.5) | |
| Region, n (%) | ||||
| Northeast | 397 (4.1) | 40 (1.2) | 357 (5.6) | < 0.0001 |
| South | 4330 (45.0) | 917 (28.5) | 3413 (53.3) | |
| Midwest | 52 (0.5) | 0 | 52 0.8) | |
| West | 4840 (50.3) | 2258 (70.2) | 2582 (40.3) | |
| Treatment naive at index, n (%) | 3940 (41.0) | 1188 (37.0) | 2752 (43.0) | < 0.0001 |
| Baseline HIV RNA viral load | 685 | 8051 | 110 | < 0.0001 |
| Median copies/ml (IQR) | (47–43,755) | (151–71,079) | (19–29,462) | |
| Baseline CD4 count | 389 | 274 | 452 | < 0.0001 |
| Median cells/μL (IQR) | (212–606) | (142–452) | (270–660) | |
| AIDS‐defining illness at or before index | 1924 (20.0) | 965 (30.0) | 959 (15.0) | < 0.0001 |
ABC = abacavir; AIDS = acquired immunodeficiency syndrome; IQR = interquartile range; MSM = men who have sex with men.
aBy screening period.